LifeM­ine’s re­struc­tur­ing; Eu­rope won’t re­new au­tho­riza­tion for PTC’s Duchenne drug

Plus, news about ​​Opthea, Apol­lomics, LaunXP and As­traZeneca:

LifeM­ine re­duces head­count: The Boston biotech went through a “com­pa­ny-wide re­struc­tur­ing,” ac­cord­ing to em­ploy­ees’ LinkedIn posts. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER